In April 2023, Mrs. Masturoh arrived at the C-Care Cancer Research Lab (Dr. Warsito’s Cancer Research) in a wheelchair, with difficulty speaking and partial memory loss. Previously, she had undergone several surgeries and three rounds of Gamma Knife treatment in 2018, but the tumor reappeared, leaving her unable to walk or talk. The type of tumor she had was challenging to treat, and the older ECCT device generally didn’t yield good results. However, with the latest ECCT development, Mrs. Masturoh was able to walk and talk normally again after two months.
Image: CT scan images of Mrs. Masturoh’s brain before using the device, after two months of use, and a recent photo after one year of use.
Her tumor type is multiple meningioma, a malignant form of cancer that attacks the brain’s protective membranes. Typically, meningiomas are benign, and with clean surgery, they don’t tend to recur. However, multiple meningioma is a malignant form of meningioma, which can spread to surrounding areas, with a high recurrence rate, especially if the surgery isn’t clean. This is what happened to Mrs. Masturoh. Since the tumor was located near the communication nerves in the left frontal part of the brain, clean surgery was difficult and posed a high risk. If the communication nerves were damaged during surgery, she might lose the ability to speak permanently.
However, if the surgery isn’t clean, it only delays the inevitable, and the tumor may return, spreading further. In such cases, a second surgery is even more difficult, with higher risks. Eventually, the tumor will spread and affect vital nerves, leading to the same outcome — an inability to communicate. It’s a difficult situation, as the cost of surgery is high, and if the surgery isn’t successful, the outcome would be the same as not having surgery at all. In some cases, it may be less risky to do nothing.
Two years after her advanced surgery with Gamma Knife, Mrs. Masturoh’s symptoms returned, including difficulty speaking and walking. An MRI showed that the tumor had reappeared and spread significantly, with lesions in the left frontal intra-axial brain area, the left frontal lobe, the anterior medial area, and the parasagittal right temporal area, each about 1-2 cm in size. The entire front left side of her brain was infected by the tumor, putting pressure on the right side of the brain, making surgery nearly impossible. Mrs. Masturoh’s condition seemed hopeless, and not much could be done. She only consumed herbal supplements in hopes of slowing the cancer’s progression.
Two years passed, and her condition worsened. In October 2022, an MRI showed that the tumor had expanded, filling more than half of her left frontal and temporal lobes and pressing into the right side of her brain. In addition to the solid mass covering a large area, there was also a cystic lesion filled with thick fluid and blood, measuring almost 5 cm.
All possible treatments had been attempted, with significant costs spent on both medical surgeries and alternative therapies, including herbal remedies. However, her condition left her unable to speak, communicate, or walk. Medically, there was little left to do, as her tumor type didn’t respond to medications or herbal treatments.
The last remaining alternative at the time was ECCT. In April 2023, Mrs. Masturoh was brought in by her husband in a wheelchair to consult about the possibility of using the ECCT device. Mrs. Masturoh could no longer speak, and her memory was fragmented. The latest MRI before using the device showed that the tumor had spread even further, accompanied by widespread edema, and the cyst had grown to more than double its size compared to six months earlier. The pressure from the mass rendered her communication and motor nerves non-functional.
The type of tumor Mrs. Masturoh had was a combination of solid and cystic components, with mixed responses to the electrical fields generated by ECCT. The solid components respond to ECCT based on the tumor’s malignancy level—the more aggressive the tumor, the faster it responds to the electrical fields, leading to cell death, shrinkage, and gradual dissolution. Meanwhile, the cystic component, essentially non-living, doesn’t respond to electrical fields like growing solid cells. The size of the cyst can fluctuate based on external and internal pressure, influenced by electrolyte and albumin levels in the blood. When electrolyte and albumin levels are normal, ECCT can act as a pump, opening ion channels in the cyst membrane, allowing fluid and material to flow out, shrinking the cyst.
However, in some post-radiation or chemotherapy cases, the cyst membrane can become very fragile. Normally, the cyst membrane, composed of lipid tissue, isn’t easily torn by physical stimulation or electrical fields. But in post-radiation cases, the membrane becomes very delicate, making it prone to rupture if the internal pressure is high or if there’s external physical or electrical stimulation. The electrical fields generated by ECCT are relatively low (a few hundred millivolts per cm), typically not strong enough to damage a normal cyst. But if the membrane is too fragile, even this low-level field can cause it to rupture, leading to the rapid release of fluid, which can have uncontrolled effects. This risk had to be carefully considered in Mrs. Masturoh’s case. Voltage settings and usage time needed to be precisely controlled to prevent the cyst from bursting suddenly.
Mrs. Masturoh’s husband received a detailed explanation and decided to try the device, as there were no other alternatives.
A custom ECCT device was created for Mrs. Masturoh with two perpendicular electrical fields, allowing the tumor to receive optimal exposure from both directions. The latest modulation system was also implemented to disrupt the mitosis process in cancer cells, causing immediate cell death during division when exposed to the field. Additionally, signal modulation was provided to aid the transport of materials from the destroyed tumor cells, helping the immune cells to absorb them more quickly. Another modulation program was also implemented to open ion channels in the cyst membrane, allowing fluids and other materials in the cyst to flow out through the membrane, mimicking the effect of opening the blood-brain barrier.
The modulation of the electrical fields in the latest ECCT development proved to be quite effective in Mrs. Masturoh’s case, which had previously been difficult to treat with the older ECCT specifications.
Mrs. Masturoh’s progress after using the newly developed ECCT was rapid. Within days, her communication and mobility began to improve, and her fragmented memory gradually returned. An MRI after two months of use showed remarkable results: the edema fluid had almost disappeared, the solid mass of malignant cells had nearly cleared, and the fluid-filled cyst had reduced to less than half its size. A scan with ECVT showed that her intracranial pressure had returned to normal.
After two months of using ECCT, and eight months of being unable to walk or talk, Mrs. Masturoh regained normal speech and mobility. When her husband brought her back to C-Care after two months, she no longer used a wheelchair, walking normally, and her usual chatty personality had fully returned. The doctor who had previously examined her was astonished when he saw her again: “Are you really Mrs. Masturoh…?”
One year after using ECCT, and five years since her Gamma Knife surgery and the tumor recurrence, Mrs. Masturoh’s condition is completely normal. Occasionally, she still feels some discomfort when using the ECCT device, possibly due to the remaining cyst fluid. When using the device, the fluid seems to be pumped out through the cyst membrane, causing some pain. Mrs. Masturoh has been advised to continue using ECCT to prevent recurrence and ensure the cyst fully shrinks.
“The side effect of continuous use of the device is that it helps prevent waste buildup in the brain, improves focus and concentration, ensures smooth blood flow, and prevents aging and dementia,” explained Dr. Warsito, the inventor of ECCT and ECVT.
We wish Mrs. Masturoh continued good health.
